For a standard, uncomplicated pregnancy, the recommended schedule for prenatal visits is every 4 weeks until 28 weeks gestation, every 2 weeks from 28 to 36 weeks, and then weekly from 36 weeks until delivery. This schedule allows for routine monitoring of maternal and fetal well-being.

Women with a history of a prior pregnancy affected by a neural tube defect (NTD) are at high risk for recurrence. The standard recommendation for these women is high-dose folic acid supplementation of 4 mg (4000 mcg) daily, starting at least one month before conception and continuing through the first trimester. The 0.4 mg (400 mcg) dose is recommended for average-risk women.

Angiotensin-converting enzyme (ACE) inhibitors like lisinopril are contraindicated in pregnancy due to their association with fetal renal dysplasia, oligohydramnios, and skull defects. They should be discontinued immediately. Given her elevated blood pressure, antihypertensive therapy is still required. Labetalol, methyldopa, and nifedipine are considered first-line agents for managing hypertension during pregnancy. Losartan is an angiotensin II receptor blocker (ARB) and carries similar teratogenic risks as ACE inhibitors.

No safe level of alcohol consumption during pregnancy has been established. All major medical organizations, including the American College of Obstetricians and Gynecologists (ACOG), recommend complete abstinence from alcohol throughout pregnancy due to the risk of fetal alcohol spectrum disorders. Recommending a 'safe' limit is inappropriate. A detailed ultrasound at this early gestation would not be able to identify features of fetal alcohol syndrome.

The classic first-trimester screening pattern for Trisomy 21 includes an increased nuchal translucency, high beta-hCG, and low PAPP-A. Trisomy 18 and Trisomy 13 are typically associated with low levels of both beta-hCG and PAPP-A. Open neural tube defects are screened for in the second trimester with maternal serum alpha-fetoprotein (MSAFP), which would be elevated.

An elevated MSAFP can be caused by several factors, including incorrect gestational dating, multiple gestation, fetal demise, or fetal anomalies such as neural tube defects or abdominal wall defects. The first step is to perform a detailed ultrasound to confirm the gestational age, assess for multiples, and carefully evaluate fetal anatomy. If the ultrasound is unrevealing, amniocentesis may be offered. CVS is not indicated as it is a first-trimester procedure and does not assess amniotic fluid AFP. Cell-free DNA testing screens for aneuploidy, not neural tube defects.

For definitive genetic diagnosis in the first trimester, chorionic villus sampling (CVS) is the procedure of choice. It is typically performed between 10 and 13 weeks gestation. Amniocentesis is performed later, usually after 15 weeks gestation. PUBS is a late-trimester procedure used for specific indications like rapid karyotyping or fetal blood transfusion. Ultrasonography can identify markers suggestive of aneuploidy but is not a diagnostic genetic test.

Universal screening for gestational diabetes mellitus (GDM) is recommended for all pregnant women between 24 and 28 weeks gestation, typically with a 1-hour 50-g glucose challenge test. Early screening in the first trimester is reserved for women with high-risk factors (e.g., severe obesity, history of GDM). Screening later than 28 weeks is not standard practice.

Universal screening for Group B Streptococcus (GBS) colonization is recommended for all pregnant women between 36 0/7 and 37 6/7 weeks gestation. This is done via a rectovaginal culture. The results guide the use of intrapartum antibiotic prophylaxis to prevent neonatal GBS disease. A 3-hour GTT is a diagnostic test for GDM, performed earlier in pregnancy. Biophysical profiles and nonstress tests are methods of fetal surveillance reserved for high-risk pregnancies or specific indications, not routine screening at this stage.

Valproic acid has the highest risk of major congenital malformations (especially neural tube defects) among commonly used antiepileptic drugs and should be avoided in women of childbearing potential if possible. Preconception counseling is the ideal time to transition to a safer alternative with a lower teratogenic risk, such as lamotrigine or levetiracetam, while ensuring continued seizure control. Discontinuing medication entirely is dangerous, and phenobarbital also carries significant teratogenic risks.